Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access for Nonconforming Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma
jRCT2053220006Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- May 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Open-label, single-arm trial of idecabtagene vicleucel in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Primary endpoint: Safety: Adverse events and laboratory abnormalities. Started May 2022; status: recruiting.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2053220006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053220006.